Fulgent Genetics, Inc. (NASDAQ:FLGT) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Fulgent Genetics, Inc. (NASDAQ:FLGT) Just Released Its Second-Quarter Earnings: Here's What Analysts Think
Fulgent Genetics, Inc. (NASDAQ:FLGT) just released its latest second-quarter results and things are looking bullish. Results overall were solid, with revenues arriving 2.8% better than analyst forecasts at US$71m. Higher revenues also resulted in substantially lower statutory losses which, at US$0.29 per share, were 2.8% smaller than the analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Fulgent Genetics, Inc.(納斯達克證券代碼:FLGT)發佈了其最新的二季度業績報告,看好前景。總體業績表現良好,營業收入爲7100萬美元,比分析師預測高出2.8%。更高的營業收入也導致法定虧損大幅下降,每股0.29美元,比分析師預測的小2.8%。盈利是投資者們關注的重點,他們可以追蹤公司的表現,查看分析師對明年的預測並觀察對該公司的情緒是否發生了變化。我們收集了最近的法定預測來看看分析師是否根據這些結果改變了其盈利模型。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240805/0-06271118f8e702b212df0dfb81784e82-0-865a94bcfad749fb89766a348f7d710d.png/big)
Taking into account the latest results, the three analysts covering Fulgent Genetics provided consensus estimates of US$280.3m revenue in 2024, which would reflect a perceptible 3.6% decline over the past 12 months. Losses are predicted to fall substantially, shrinking 62% to US$2.06. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$280.2m and losses of US$2.31 per share in 2024. While the revenue estimates were largely unchanged, sentiment seems to have improved, with the analysts upgrading their numbers and making a favorable reduction in losses per share in particular.
綜合最新成果,涉及Fulgent Genetics的三名分析師提供2024年2,8030萬美元的營收共識預測,這將反映過去12個月中逐漸下降的3.6%。預測虧損將大幅縮小,降低62%至2.06美元。但在最新的盈利數據公佈之前,分析師對2024年的營收預測爲2,8020萬美元,每股虧損預測爲2.31美元。雖然營收預測基本沒有變化,但是情緒似乎得到了改善,分析師們提高了其數字,特別是在每股虧損方面做出了有利的減少。
There's been no major changes to the consensus price target of US$27.33, suggesting that reduced loss estimates are not enough to have a long-term positive impact on the stock's valuation. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Fulgent Genetics at US$30.00 per share, while the most bearish prices it at US$25.00. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.
美元27.33元的一致價格目標沒有發生重大變化,這表明減少的虧損估計還不足以對股票的估值產生長期積極的影響。檢視分析師估值的範圍可能會有所啓示,以評估異常意見相對於平均值的差異。目前最看好的分析師認爲每股Fulgent Genetics價值30.00美元,而最看淡的則將其定爲25.00美元。儘管這些估值之間相差無幾,但這表明分析師們對該公司的價值有一個相對明確的想法。
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Fulgent Genetics' past performance and to peers in the same industry. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 7.1% by the end of 2024. This indicates a significant reduction from annual growth of 14% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 6.8% annually for the foreseeable future. It's pretty clear that Fulgent Genetics' revenues are expected to perform substantially worse than the wider industry.
這些估值很有趣,但更重要的是在比較預測與Fulgent Genetics過去的表現以及同行業同樣受分析師關注的公司表現時,描繪一些更廣泛的筆觸就可能非常有用了。這些估計表明,預計營收將減緩,預計至2024年底年化下降7.1%。這意味着與過去5年的年均增長14%相比,出現了明顯的降低。相比之下,我們的數據表明,同一行業(受到分析師關注的)的其他公司在可預見的未來預計年均增長6.8%。很明顯,Fulgent Genetics的營收預計表現將顯著遜於整個行業。
The Bottom Line
最重要的事情是分析師增加了它對下一年每股虧損的估計。令人欣慰的是,營收預測未發生重大變化,業務仍有望比整個行業增長更快。共識價格目標穩定在28.50美元,最新估計不足以對價格目標產生影響。
The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at US$27.33, with the latest estimates not enough to have an impact on their price targets.
需要重點注意的是,分析師們確認了明年每股虧損的估計值。好的一面是營收預測沒有發生重大變化;雖然預測表明它們將表現得比整個行業差,但是共識的價格目標保持在27.33美元,並且最新的估值不足以對其價格目標產生影響。
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have estimates - from multiple Fulgent Genetics analysts - going out to 2026, and you can see them free on our platform here.
在此基礎上,請記住,我們仍然認爲公司的長期軌跡對投資者更爲重要。我們從多個Fulgent Genetics的分析師處得到2026年的預測,您可以在此處免費查看這些預測。
We also provide an overview of the Fulgent Genetics Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.
此外,我們介紹了Fulgent Genetics董事會和首席執行官的報酬及在公司任職時間以及內部人士是否購買該股票的概述,點擊此處查看。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。